Toray Industries has opened the Toray Taiwan Technical Center. This new facility aims to enhance research and development in advanced semiconductor technologies and materials, and provide technical services in the Taiwan market, which plays a significant role in the global semiconductor supply chain.
Eli Lilly plans to invest $27 billion to bolster its domestic medicine production across several therapeutic areas by building four new manufacturing sites in the US.
The 15% capacity expansion of Arkema’s PVDF production site in Calvert City, Kentucky, represents an investment of approximately $20 million (€19 million).
BASF India Ltd. has broken ground on a new plant to increase the production capacity of its Cellasto microcellular polyurethane (MCU) in Dahej, India.
Nouryon plans to expand its chromatography media manufacturing facility in Bohus, Sweden, doubling the site’s capacity. Construction will begin in early 2025, and the start of production is expected in early 2027, the company said.
Henkel recently announced the opening of its new Application Center in Busan, South Korea, marking a significant investment in the global sports & fashion industry.
German specialty chemicals company Lanxess inaugurated its India Application Development Center (IADC) in Mumbai.
TotalEnergies and Air Liquide have signed agreements to develop two projects in the Netherlands, for the production and delivery of some 45,000 t/y of green hydrogen produced using renewable power, generated mostly by the OranjeWind offshore wind farm, developed by TotalEnergies (50%) and RWE (50%).
Fujifilm plans to invest approximately €25 million to install new production facilities for chemical mechanical planarization (CMP) slurries, which are used in advanced semiconductors, as well as enhance existing facilities for photolithography-related materials at its site in Antwerp, Belgium.
Global integrated energy group OQ announced that three companies, representing a combined investment of $42 million, will start operations at Oman’s Ladayn Polymer Park in early 2025.
Spanish energy and petrochemicals group Repsol has approved an investment of more than €800 million to build its Ecoplant in the area of Tarragona, Spain. The first of its kind in Europe, the facility will use urban waste to produce renewable fuels and circular products through gasification, the company said.
UK contract development and manufacturing organization (CDMO) Upperton Pharma Solutions, has completed its new sterile manufacturing facility in Nottingham, UK, expanding its capacity in addition to its existing 50,000-square-foot site at Trent Gateway.
Solvias, a Switzerland-headquartered provider of chemistry, manufacturing, and control (CMC) analytics, has opened the first phase of its 50,000-square-foot testing center for biologics and cell and gene therapy in Research Triangle Park (RTP), North Carolina, US.
To support the move to a larger office facility in the Greater Toronto Area, Ontario, AstraZeneca plans to invest $570 million in Canada, creating more than 700 jobs.
At the end of last week, US biotech Amgen officially opened its newest drug substance facility in Holly Springs, North Carolina, US. The opening day also saw the groundbreaking of a further $1 billion expansion at the North Carolina site, announced less than two months ago.
AkzoNobel has proposed a €22 million investment to make its Montataire site a flagship for decorative paint production in France.
French green chemistry company Carbios announced that it is postponing the construction of its PET bio-recycling plant in Longlaville for six to nine months due to delayed funding pending completion of additional financing under satisfactory conditions. The company aims to complete the financing as soon as possible to meet market needs from 2027. Carbios expects to sign several binding commercial contracts in the first half of 2025.
German family-owned industrial gases producer Messer has started operations at a new plant for the production of green carbon dioxide (CO2) at its Vrdy site in the Czech Republic.
Japan’s Toray Industries plans to install a pilot facility for its all-carbon carbon dioxide (CO2) separation membrane at its plant in Shiga, Japan.
Clariant is expanding its Cangzhou production site to manufacture the multifunctional additive Nylostab S-EED.
Danish drugmaker Novo Nordisk plans to invest 8.5 billion Danish kroner (about €1.14 billion) to establish a new production facility in Odense, Denmark.
Ineos and its partners Harbour Energy and Nordsøfonden have taken the final investment decision (FID) into the first commercial phase ‘Greensand Future’ with storage operations in a depleted oil field in the Danish North Sea set to begin at the end of 2025/early 2026.
In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.
US drug manufacturer Eli Lilly announced a $3 billion expansion of its US manufacturing facility in Kenosha County, Wisconsin, that the company acquired earlier this year. This investment will extend the company's global parenteral (injectable) product manufacturing network for diabetes, obesity and future medicines across therapeutic areas.
Sanofi plans to invest around €1 billion ($1.1 billion) in the construction of a new insulin production facility in Beijing – the company's largest single investment in China to date. This was reported by Reuters and other news agencies.
In a move to increase its competitive advantage in Latin America, Swiss flavors, fragrances and active cosmetic ingredients manufacturer Givaudan has inaugurated its newly expanded production facility at the Pedro Escobedo site in Mexico, enhancing the company’s encapsulation technologies.
French industrial gases group Air Liquide is launching a renewable hydrogen production project at La Mède, France, to supply TotalEnergies’ biorefinery at that site under a long-term contract. AirLiquide will build, own, and operate the new unit with a capacity of 25,000 t/y, producing hydrogen from recycled biogenic by-products instead of fossil hydrocarbons.
Japanese chemical group Ube wants to increase production capacity for high-purity nitric acid at its chemical plant in Ube City, Yamaguchi Prefecture.
Lisbon, Portugal-headquartered Hovione has completed significant expansions in Europe and the USA. The investments at the facilities in East Windsor, New Jersey, and Ringaskiddy, Cork, significantly increase the global capacities of the CDMO (contract development and manufacturing organization) for spray drying for pharma applications and improve the sites' capabilities.
Abu Dhabi National Oil Company (ADNOC) has launched XRG, an international lower-carbon energy and chemicals investment company, with an enterprise value of over $80 billion.
Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.
IMCD Group, a global distribution partner and formulator of specialty chemicals and ingredients, recently announced the expansion of its Pharmaceuticals Technical Centre in Jakarta, Indonesia. This facility will serve as the hub for pharmaceutical development and innovation across Southeast Asia, Australia, and New Zealand.
Avantor has opened its latest Innovation Center in Bridgewater, New Jersey, US, “to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows.” The new center is now part of the company’s network of 13 global research and innovation centers.
Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.
Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.
